Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1
- PMID: 12888575
- DOI: 10.1074/jbc.M305019200
Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1
Abstract
Fibrotic diseases such as scleroderma (systemic sclerosis, SSc) are characterized by an excessive production of extracellular matrix and profibrotic proteins such as connective tissue growth factor (CTGF). In normal dermal fibroblasts, CTGF is not expressed unless induced by proteins such as tumor growth factor-beta (TGFbeta). Conversely, in fibroblasts cultured from fibrotic lesions CTGF mRNA and protein are constitutively expressed, even in the absence of exogenously added TGFbeta. Thus, studying the mechanism underlying CTGF overexpression in SSc fibroblasts is likely to yield valuable insights into the basis of the fibrotic phenotype of SSc and possibly other scarring disease. CTGF overexpression is mediated primarily by sequences in the CTGF promoter. In this report, we identify the minimal promoter element involved with the overexpression of CTGF in SSc fibroblasts. This element is distinct from the element necessary and sufficient for the induction of CTGF expression by TGFbeta in normal fibroblasts. Within this region is a functional Sp1 binding site. Blocking Sp1 activity reduces the elevated, constitutive levels of CTGF promoter activity and protein expression observed in SSc fibroblasts. Relative to those prepared from normal dermal fibroblasts, nuclear extracts prepared from SSc fibroblasts possess increased Sp1 binding activity. Removal of phosphate groups from nuclear extracts enhanced Sp1 binding activity, suggesting that phosphorylation of Sp1 normally reduces Sp1 binding to DNA. Thus, the constitutive overexpression of CTGF in SSc fibroblasts seems to be independent of TGFbeta signaling but dependent at least in part on Sp1.
Similar articles
-
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.J Biol Chem. 2001 Apr 6;276(14):10594-601. doi: 10.1074/jbc.M010149200. Epub 2001 Jan 4. J Biol Chem. 2001. PMID: 11152469
-
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis.Exp Cell Res. 2000 Aug 25;259(1):213-24. doi: 10.1006/excr.2000.4972. Exp Cell Res. 2000. PMID: 10942593
-
Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis.Keio J Med. 2004 Jun;53(2):74-7. doi: 10.2302/kjm.53.74. Keio J Med. 2004. PMID: 15247510 Review.
-
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts.Mol Pathol. 2001 Jun;54(3):180-3. doi: 10.1136/mp.54.3.180. Mol Pathol. 2001. PMID: 11376132 Free PMC article.
-
Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis.Curr Opin Rheumatol. 2001 Nov;13(6):505-11. doi: 10.1097/00002281-200111000-00010. Curr Opin Rheumatol. 2001. PMID: 11698729 Review.
Cited by
-
Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine.Am J Pathol. 2008 Jun;172(6):1675-82. doi: 10.2353/ajpath.2008.070952. Epub 2008 May 8. Am J Pathol. 2008. PMID: 18467695 Free PMC article.
-
Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK.J Cell Commun Signal. 2007 Sep;1(2):85-90. doi: 10.1007/s12079-007-0008-9. Epub 2007 Jul 17. J Cell Commun Signal. 2007. PMID: 18481199 Free PMC article.
-
Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.Biochim Biophys Acta. 2013 Jul;1832(7):911-21. doi: 10.1016/j.bbadis.2013.03.001. Epub 2013 Mar 14. Biochim Biophys Acta. 2013. PMID: 23499992 Free PMC article.
-
Autoimmune mechanisms of scleroderma and a role of oxidative stress.Self Nonself. 2011 Jan;2(1):4-10. doi: 10.4161/self.2.1.14058. Epub 2011 Jan 1. Self Nonself. 2011. PMID: 21776329 Free PMC article.
-
Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors.J Cell Mol Med. 2009 Aug;13(8B):2353-64. doi: 10.1111/j.1582-4934.2009.00674.x. J Cell Mol Med. 2009. PMID: 20141616 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous